Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hamza Mahmood Bajwa

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 22, 2024
Extended interval dosing with ocrelizumab in multiple sclerosisFrederik Novak, Hamza Mahmood Bajwa, Kamilla Østergaard, et al.
Multiple Sclerosis and Related Disorders|March 25, 2022
Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patientsHamza Mahmood Bajwa, Frederik Novak, Anna Christine Nilsson, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 15, 2023
Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA vaccine dosesFrederik Novak, Hamza Mahmood Bajwa, John Eugenio Coia, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 22, 2024
Extended interval dosing with ocrelizumab in multiple sclerosisFrederik Novak, Hamza Mahmood Bajwa, Kamilla Østergaard, et al.
Multiple Sclerosis and Related Disorders|March 25, 2022
Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patientsHamza Mahmood Bajwa, Frederik Novak, Anna Christine Nilsson, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 15, 2023
Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA vaccine dosesFrederik Novak, Hamza Mahmood Bajwa, John Eugenio Coia, et al.
Pageof 1